|
 |
Diabetes > Antagonist
The following information is about Antagonist.
Antagonist Defined
One agent that opposes or fights the action of another. For example, insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it; therefore, insulin and glucagon are antagonists.
This definition is in context to Diabetes. See more contextual defintions for Antagonist.
Schering-Plough announces phase II and III data for corifollitropin alfa
Published July 2, 2009, 9:48 pm, PharmaBiz
Schering-Plough Corp., announced results from the phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
Published July 2, 2009, 9:08 am, Medical News Today
Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability.
My Pharmiweb.com
Published July 2, 2009, 3:49 am, PharmiWeb
AMSTERDAM, THE NETHERLANDS , July 1, 2009 -- Schering-Plough Corp ., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Theravance Announces New Employment Inducement Awards
Published July 1, 2009, 5:33 pm, Marketwire
SOUTH SAN FRANCISCO, CA--(Marketwire - July 1, 2009) - Theravance, Inc. ( NASDAQ : THRX ) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of ...
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Published July 1, 2009, 6:00 am, PR Newswire via Yahoo! Finance
dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The ...
Published July 1, 2009, 4:10 am, Medical News Today
Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211.
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the ...
Published June 30, 2009, 7:18 am, redOrbit
Results Demonstrate Positive Proof of Mechanism SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc.
Sosei And Vectura Announce Start Of Phase III Clinical Study With NVA237
Published June 30, 2009, 4:09 am, Medical News Today
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).
Washington Editor
Published June 29, 2009, 5:27 pm, BioWorld
Shares of Vectura Group plc rose 8.5 percent on the London stock exchange Monday after the Chippenham, UK-based firm and its partner, Sosei Group Corp., of Tokyo, said Novartis AG had initiated a Phase III study of NVA237, a dry powder formulation of the muscarinic antagonist glycopyrronium bromide, as an inhalational treatment for chronic obstructive pulmonary disease.
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Published June 29, 2009, 3:59 am, redOrbit
CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ -- - Study Triggers $7.5m Milestones for Both Companies Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary ...
Are you looking for additional Diabetes > Antagonist news? Try our new "Antagonist News Focus" area.
Off-site Antagonist Links, User Submitted
The following links have been collected through user bookmark submission in the Antagonist category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Tue Jun 23
Tue Jun 9
- Naltrexone - An Antagonist Therapy for Heroin Addiction: Deals with naltrexone 9;s effect on the brain and why it is not used more.
Mon May 25
- The Antagonist: This is my blog. I find it's easier post regularly if there's some purpose to it. It's not a personal life thing, which I always find weird, but it's all about the Magazine, and that's something I can talk about endlessly.
Sat May 23
- BBC NEWS | Americas | Meet America's 'toughest sheriff': "At the end of his visit, he even signed some autographs in postcards provided by the jail, featuring him next to a pink fluorescent Vacancy sign and the words 'If you don't want to do the time? don't do the crime', taken when the sheriff first opened this prison. 'When he dies this will be valuable!' ; one inmate shouted to others in Spanish."
Wed May 13
- Google's mobile jihad: Support the web, live with the app: Over the last year, it's become clear that Google has a bigger war on its hands in mobile than it had anticipated. It's principal antagonist is sexy Apple iPhone, which has seriously disrupted Google's ambitions to turn mobile industry into a Web-based ...
Fri May 8
Tue May 5
- Where Do You Start Your Book or Story?: Ideas and tips for starting a book or story.
- Characters in the Story: Characters in your story; who are they and what are they doing?
Wed Apr 29
- Worldchanging: Bright Green: Geoengineering and the New Climate Denialism
- Malaria versus the human genome
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Antagonist. If you would like to find related tags we recommend Tag Patterns > Antagonist
Off-site Antagonist Research Links
If you still need additional information on Antagonist then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
- A9 > Antagonist
- Alexa > Antagonist
- Anti-Aging Revolution > Antagonist
- DMOZ > Antagonist
- Feeds Filtered > Antagonist
- Google > Antagonist
- News Meme > Antagonist
- Nuah: News > Antagonist
- The Feed Directory > Antagonist
- OBP > Antagonist
- Open Tag Directory > Antagonist
- Podzy > Antagonist
- Yahoo > Antagonist
Diabetes Topics
Everything you need to know about Diabetes
Diabetes
If you know the Diabetes Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Diabetes.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
License
This work is licensed under Creative Commons.